Aggressive CNS lupus vasculitis in the absence of systemic disease activity.
Everett
C M
CM
Department of Molecular Neuroscience and Centre for Neuromuscular Disease, Institute of Neurology and the National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
Graves
T D
TD
Lad
S
S
Jäger
H R
HR
Thom
M
M
Isenberg
D A
DA
Hanna
M G
MG
D000927:Anticonvulsants / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood*; D001379:Azathioprine / Q000627:therapeutic use; D001921:Brain / Q000473:pathology* / Q000503:physiopathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007275:Injections, Intravenous; D020945:Lupus Vasculitis, Central Nervous System / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D012640:Seizures / Q000175:diagnosis / Q000209:etiology; D012698:Serologic Tests; D016896:Treatment Outcome
D000927:Anticonvulsants; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents; D010672:Phenytoin; D003520:Cyclophosphamide; D001379:Azathioprine; D008775:Methylprednisolone